title: [Clinical features and outcome analysis of 83 childhood Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-2004 protocol].
abstract: OBJECTIVE
  To investigate the clinical features of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH), to analysis the outcome of HLH-2004 protocol, and to explore the prognostic factors in EBV-HLH patients.
  
  
  METHODS
  The clinical features at onset and outcome of HLH-2004 protocol from 83 pediatric patients with EBV-HLH enrolled from January 2006 to December 2009 in our hospital were analyzed retrospectively. Univariate and multivariate COX regression analysis were used to identify statistically significant prognostic factors.
  
  
  RESULTS
  (1) Among the 83 patients, 45 were males and 38 were females. The age of onset ranged from 6 months to 14 years 4 months. 44 patients were treated with HLH-2004, and 3-year overall survival (OS) was (55.8 ± 7.9)%. (2) The most common clinical features of EBV-HLH included high fever, cytopenia, hepatosplenomegaly, and coagulopathy; The respiratory symptoms, angina phlogistic, skin rashes, neurologic abnormality were rare. 97.3% of patients showed an elevation of serum ferritin, liver dysfunction and lipid metabolism disorders was found in most of EBV-HLH patients. 89.0% of patient had hemophagocytosis in bone marrow at diagnosis of EBV-HLH. (3) COX regression analysis revealed that anemia degree, serum albumin < 30 g/L, CD4:CD8 abnormity, NK cell < 3%, treatment protocol were related with the prognosis significantly (P < 0.05).
  
  
  CONCLUSIONS
  EBV-HLH in pediatric patients has severe clinical feature and poor prognosis. HLH-2004 protocol is an effective treatment for patients with EBV-HLH. Symptomatic treatment can't rescue the patients of EBV-HLH.
authors.affiliation: Department of Hemooncology, Chongqing Medical University, Chongqing, China.
authors.forename: Li
authors.initials: L
authors.lastname: Xiao
authors.forename: Ying
authors.initials: Y
authors.lastname: Xian
authors.forename: Bi-tao
authors.initials: BT
authors.lastname: Dai
authors.forename: Yong-chun
authors.initials: YC
authors.lastname: Su
authors.forename: Jian-wen
authors.initials: JW
authors.lastname: Xiao
authors.forename: Qi-cheng
authors.initials: QC
authors.lastname: Zheng
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Zhao
authors.forename: Jie
authors.initials: J
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy*; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D007223:Infant; D007694:Killer Cells, Natural; D051359:Lymphohistiocytosis, Hemophagocytic / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome